Chapter 9: Endocrine Health and Disease


Human Endocrine System

The endocrine system consists of glands that produce and secrete hormones; chemical substances produced in the body that manages the body’s growth, metabolism, and sexual maturation and function. The hormones are discharged into the bloodstream and may affect one or several organs throughout the body. Hormones are chemical carriers produced by the body. They convey information from one set of cells to another to regulate the functions of different members of the body. The central glands of the endocrine system are the hypothalamus, pituitary, thyroid, parathyroid, adrenals, pineal body, and the reproductive organs (ovaries and testes). Other organs in the body also produce hormones these include the heart, stomach, pancreas and small intestine, however, unlike the exocrine system, the endocrine system is ductless; it disperses hormones directly into the bloodstream. Similar to the nervous system the endocrine system conveys information, but it does it through chemical reactions and not electrical signals. The result is a slow initiation and a lengthy response which can last a few hours or weeks.1

Role of CBD in Endocrine Disorders and Diseases

A collection of glands that signal each other in sequence is an axis, such as the hypothalamic-pituitary-adrenal axis. An increasing amount of data is indicating the role of the endocannabinoid system in regulating stress responses by influencing this axis. Studies have also shown the effects of the ECS in the control of the reproductive system through gonadotropin release adjustment, fertility, and even sexual behavior. Such results support to essential role cannabinoids play in preserving hormonal homeostasis, and therefore their eligibility in the treatment of endocrine conditions.2


Diabetes is an endocrine dysfunction with a firm ancestral element, affecting children and adults permanently. The extension of insulin resistance and glucose dysregulation characterizes diabetes mellitus and impacts the cardiovascular, immunological, neurological and the endocrine system. Clinical endocannabinoid deficiency (CECD), defined as genetic and acquired, affects both excitatory CB1 receptors and immune-responsive CB2 receptors in the endocrine system. An overactive endocannabinoid system that has hyperactive CB1 receptors is associated with oxidative and nitrative stress, inflammation, increased insulin resistance and increased appetite.

Research supports the benefits of cannabidiol (CBD) in decreasing insulin resistance and as a hypoglycemic agent. Two groups of mice showing initial symptoms of diabetes were used in a study, where some were given controlled CBD, and others received no treatment. The experiment concluded that only 32% of the CBD treated group developed diabetes, where 100% of the untreated group developed diabetes. Preventatively in healthy and in people at risk for diabetes mellitus, cannabidiol is suggested to improve disease management and prevent secondary manifestations of the disease, such as diabetic neuropathy.2-32


The thyroid is a gland is at the bottom of the next above the collarbone. This gland manages a series of functions, such a the heartbeat pace, and the rate of burning calories. The hormones released from the thyroid regulate the metabolism of the body.

Hypothyroidism is a disease that relates to an overactive thyroid; it produces an excess amount of the thyroxine hormone. Consequently leading to complications that include weight gain, fatigue, immune dysfunction and imbalance in internal temperature. Hypothyroidism is an idiopathic autoimmune and genetic, clinical endocannabinoid deficiency (CECD) that directly affects CB1 receptors. Several treatments help in the management of this disease. Cannabidiol oil is effective in reducing the symptoms and improving CB1 receptivity. CBD oil can be used as an adjunctive treatment and also as a preventative in individuals at risk of developing hypothyroidism.33

Thyroid Cancer

There are four main classifications of thyroid cancer, ranging from the most common papillary cancer which can usually be cured to the more aggressive and harder to cure anaplastic thyroid cancer. Generally, thyroid cancer occurs when malignant cells form in the tissues of the thyroid glands and can affect any age group. Signs of the disease include swelling or lumping in the neck and is usually detected through examining the neck and testing the blood.

Thyroid cancer is an idiopathic autoimmune clinical endocannabinoid deficiency (CECD); its symptoms include fatigue, depression, and difficulties in breathing and swallowing. It reduces the ability of CB2 receptors in eradicating the malignancy through the immune system. Research has shown that cannabidiol (CBD) has anti-tumoral benefits. The therapeutic administration of CBD is beneficial as an adjunctive and preventative treatment. Human studies suggest that cannabidiol can inhibit cancerous cells from spreading.34


  1. Johnstone C, Hendry C, Farley A, McLafferty E. Endocrine system: part 1. Nurs Stand. 2014 May 27;28(38):42-9 Available at
  2. Uberto Pagotto, Giovanni Marsicano, Daniela Cota, Beat Lutz, Renato Pasquali; The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance, Endocrine Reviews, Volume 27, Issue 1, 1 February 2006, Pages 73–100, available at
  3. Gertsch, J. (2017) Cannabimimetic phytochemicals in the diet – an evolutionary link to food selection and metabolic stress adaptation?. British Journal of Pharmacology, 174: 1464–1483, available at
  4. Lipina, C., & Hundal, H. S. (2017). The endocannabinoid system: no longer anonymous in the control of nitrergic signalling? Journal of Molecular Cell Biology, 9(2), 91-103, available at
  5. George W. Booz, Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress, Free Radical Biology and Medicine, Volume 51, Issue 5, 2011, Pages 1054-1061, ISSN 0891-5849, available at:
  6. El-Remessy, Azza B. et al. Neuroprotective Effect of(−)Δ9-Tetrahydrocannabinol and Cannabidiol in N-Methyl-d-Aspartate-Induced Retinal Neurotoxicity. The American Journal of Pathology , Volume 163 , Issue 5 , 1997 – 2008, available at
  7. Liou G, El-Remessy A, Ibrahim A, et al. Cannabidiol As a Putative Novel Therapy for Diabetic Retinopathy: A Postulated Mechanism of Action as an Entry Point for Biomarker-Guided Clinical Development. Current pharmacogenomics and personalized medicine. 2009;7(3):215-222. Available at
  8. Hayakawa, K. , Mishima, K. , Nozako, M. , Hazekawa, M. , Irie, K. , Fujioka, M. , Orito, K. , Abe, K. , Hasebe, N. , Egashira, N. , Iwasaki, K. and Fujiwara, M. (2007), Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor‐independent myeloperoxidase‐inhibiting mechanism. Journal of Neurochemistry, 102: 1488-1496. Available at
  9. Hind, W. H., England, T. J., and O’Sullivan, S. E. (2016) Cannabidiol protects an in vitro model of the blood–brain barrier from oxygen‐glucose deprivation via PPARγ and 5‐HT1A receptors. British Journal of Pharmacology, 173: 815–825. Available at
  10. Parray, H.A. & Yun, J.W. Cannabidiol promotes browning in 3T3-L1 adipocytes. Mol Cell Biochem (2016) 416: 131.
  11. Gregory I. Liou, John A. Auchampach, Cecilia J. Hillard, Gu Zhu, Bilal Yousufzai, Salman Mian, Sohail Khan, Yousuf Khalifa; Mediation of Cannabidiol Anti-inflammation in the Retina by Equilibrative Nucleoside Transporter and A2A Adenosine Receptor. Invest. Ophthalmol. Vis. Sci. 2008;49(12):5526-5531. Available at
  12. El-Remessy, Azza B. et al. Neuroprotective and Blood-Retinal Barrier-Preserving Effects of Cannabidiol in Experimental Diabetes The American Journal of Pathology, Volume 168, Issue 1, 235 – 244 (2006) available at
  13. Zuardi, Antonio Waldo. (2008). Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Revista Brasileira de Psiquiatria, 30(3), 271-280. Available at
  14. Fernández-Ruiz, J., Sagredo, O., Pazos, M. R., García, C., Pertwee, R., Mechoulam, R., & Martínez-Orgado, J. (2013). Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? British Journal of Clinical Pharmacology, 75(2), 323–333. Available at
  15. Ashleigh L. Osborne, Nadia Solowij, Katrina Weston-Green, A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia, Neuroscience & Biobehavioral Reviews, Volume 72, 2017, Pages 310-324, ISSN 0149-7634, available at
  16. Szaflarski, Jerzy P. et al. Cannabis, cannabidiol, and epilepsy — From receptors to clinical response, Epilepsy & Behavior , Volume 41 , 277 – 282 (2014), availble at
  17. Jan Malte Bumb, Frank Enning & F Markus Leweke (2015) Drug repurposing and emerging adjunctive treatments for schizophrenia, Expert Opinion on Pharmacotherapy, 16:7, 1049-1067, available at
  18. Baron, E. P. (2015), Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It’s Been …. Headache: The Journal of Head and Face Pain, 55: 885-916. Available at
  19. Yu, Y., Chen, H., & Su, S. B. (2015). Neuroinflammatory responses in diabetic retinopathy. Journal of Neuroinflammation, 12, 141. Available at
  20. Tam, J., Liu, J., Mukhopadhyay, B., Cinar, R., Godlewski, G., & Kunos, G. (2011). Endocannabinoids in Liver Disease. Hepatology (Baltimore, Md.), 53(1), 346–355. Available at
  21. Silveira, J. W., Issy, A. C., Castania, V. A., Salmon, C. E. G., Nogueira-Barbosa, M. H., Guimarães, F. S., … Bel, E. D. (2014). Protective Effects of Cannabidiol on Lesion-Induced Intervertebral Disc Degeneration. PLoS ONE, 9(12), e113161. Available at
  22. Marcelo H. Napimoga, Bruno B. Benatti, Flavia O. Lima, Polyanna M. Alves, Alline C. Campos, Diego R. Pena-dos-Santos, Fernando P. Severino, Fernando Q. Cunha, Francisco S. Guimarães, Cannabidiol decreases bone resorption by inhibiting RANK/RANKL expression and pro-inflammatory cytokines during experimental periodontitis in rats, International Immunopharmacology, Volume 9, Issue 2, 2009, Pages 216-222, ISSN 1567-5769, available at
  23. Robson, P. J. (2014), Therapeutic potential of cannabinoid medicines. Drug Test. Analysis, 6: 24-30. Available at
  24. Stanley, C. P., Hind, W. H., & O’Sullivan, S. E. (2013). Is the cardiovascular system a therapeutic target for cannabidiol? British Journal of Clinical Pharmacology, 75(2), 313–322. Available at
  25. Rajesh, M., Mukhopadhyay, P., Bátkai, S., Patel, V., Saito, K., Matsumoto, S., … Pacher, P. (2010). Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, inflammatory and cell death signaling pathways in diabetic cardiomyopathy. Journal of the American College of Cardiology, 56(25), 2115–2125. Available at
  26. Ronen Durst, Haim Danenberg, Ruth Gallily, Raphael Mechoulam, Keren Meir, Etty Grad, Ronen Beeri, Thea Pugatsch, Elizabet Tarsish, and Chaim Lotan, Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. American Journal of Physiology-Heart and Circulatory Physiology 2007 293:6, H3602-H3607 available at
  27. Walsh, S. K., Hepburn, C. Y., Kane, K. A. and Wainwright, C. L. (2010), Acute administration of cannabidiol in vivo suppresses ischaemia‐induced cardiac arrhythmias and reduces infarct size when given at reperfusion. British Journal of Pharmacology, 160: 1234-1242. Available at
  28. Rajesh, M., Mukhopadhyay, P., Bátkai, S., Haskó, G., Liaudet, L., Drel, V. R., … Pacher, P. (2007). Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. American Journal of Physiology. Heart and Circulatory Physiology, 293(1), H610–H619. Available at
  29. Natalia Battista, Monica Bari, Cinzia Rapino, Federica Trasatti, Antonella D’Agostino & Mauro Maccarrone (2009) Regulation of female fertility by the endocannabinoid system, Human Fertility, 10:4, 207-216, available at
  30. T. Karasu, T.H. Marczylo, M. Maccarrone, J.C. Konje; The role of sex steroid hormones, cytokines and the endocannabinoid system in female fertility, Human Reproduction Update, Volume 17, Issue 3, 1 May 2011, Pages 347–361, available at
  31. Gruden, G., Barutta, F., Kunos, G., & Pacher, P. (2016). Role of the endocannabinoid system in diabetes and diabetic complications. British Journal of Pharmacology, 173(7), 1116–1127. Available at
  32. Weiss, L., Zeira, M., Reich, S., Slavin, S., Raz, I., Mechoulam, R., & Gallily, R. (2008). Cannabidiol Arrests Onset of Autoimmune Diabetes in NOD Mice. Neuropharmacology, 54(1), 244–249. Available at
  33. Malhotra S, Heptulla RA, Homel P, Motaghedi R. (2017). Effects of Marijuana Use on Thyroid Function and Autoimmunity, Pages 167-173, Available at
  34. Bifulco M, Malfitano AM, Pisanti S, Laezza C. (2008). Endocannabinoids in endocrine and related tumours. Pages 391-408. Available at